United News of Bangladesh

FC Barcelona fans have received frustrating news regarding two of their young stars, Gavi and Fermin Lopez. Gavi is scheduled for surgery on his right knee, while Fermin Lopez will be out for around three weeks with a muscle injury. Gavi to undergo knee surgery Gavi has been dealing with persistent knee pain that caused him to miss Barcelona’s recent matches against Rayo Vallecano, Valencia, Newcastle United, and Getafe. After pulling out of the Spain national team and seeing no improvement, manager Hansi Flick pushed for an immediate resolution to the case. A more detailed examination revealed a meniscus issue in his right knee. On Monday, the club decided that the best course of action was an arthroscopic examination, particularly because it involves the same knee that was previously operated on. In an official statement, Barcelona announced, “Gavi underwent intense sporting stress tests after finishing his conservation course of treatment for the radial injury to the internal meniscus in his right knee. "The conclusion is that in order to guarantee the best possible recovery and return to competitive action, this Tuesday the player will undergo an arthroscopic examination.” Surgeon Joan Carles Monllau, who previously operated on Gavi’s serious cruciate ligament injury in the same leg, will perform the procedure again under the supervision of the club’s medical staff. According to Diario AS, the midfielder is expected to be sidelined for five to six weeks. This timeline means Gavi will likely target a return in November. He is expected to miss at least seven Barcelona matches, including the El Clasico against Real Madrid on October 26th. Playing in a high-stakes match of that magnitude so soon after surgery is unlikely. Fermin out for three weeks Barcelona also confirmed Fermin Lopez’s injury on the same day. He was substituted in the 60th minute of Sunday’s 3-0 victory over Getafe due to a muscle injury. According to the club’s medical report, Fermin Lopez has an iliopsoas muscle injury in his left leg and will be out of action for approximately three weeks. This setback will likely cause him to miss matches against Real Oviedo, Real Sociedad, PSG, and Sevilla. His name is also unlikely to appear on Luis de la Fuente’s squad list for the Spain national team’s matches against Georgia and Bulgaria in October. Due to their injuries, both players will miss key upcoming matches. Gavi is expected to miss fixtures against Real Oviedo, Real Sociedad, Paris Saint-Germain, and Sevilla before the international break. Before El Clásico, Barcelona will face Girona in La Liga and Olympiakos in the Champions League. After the Clásico, the club will host Elche, a game in which the 21-year-old’s availability is also uncertain.

Head of Delegation of the European Union to Bangladesh Ambassador Rensje Teerink has said ‘Team Europe’ will share with low- and middle-income countries at least 100 million doses of Covid-19 vaccines by the end of 2021, mainly via Covax.  "Ensuring access to safe and affordable Covid-19 vaccines around the world is a priority for the EU," she told UNB while giving an overview of what the EU is contributing under Covax.  The Ambassador said Team Europe (the EU, its institutions and all 27 member states) is on track to exceed this goal, with 200 million doses of Covid-19 vaccines foreseen to be shared with the countries that need them most, by the end of 2021. Also read: EU looking closely at Bangladesh: Teerink Teerink said Covax has so far delivered 122 million doses to 136 countries. 

Gavi, the Vaccine Alliance, has signed advance purchase agreements (APAs) with China's Sinopharm and Sinovac to provide up to 550 million Covid-19 vaccines to the COVAX programme immediately. The new deals include up to 170 million doses of the Sinopharm vaccine and up to 380 million shots of the Sinovac vaccine, until mid-2022, Gavi said in a statement Monday. "The agreements, which come at a time when the Delta variant is posing a rising risk to health systems, will begin to make 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses," the statement read.  READ: Bangladesh hopeful of receiving 3.5 mln vaccine doses from COVAX this month: FM "This is yet another example of Gavi's active portfolio management strategy, ensuring the Facility has options in the face of constraints such as supply delays. Thanks to this deal, and because these vaccines have already received WHO Emergency Use Listing, we can move to start supplying doses to countries immediately," said Dr Seth Berkley, CEO of Gavi. The Sinopharm APA enables Q3 supply, with Gavi committing to purchase, on behalf of the COVAX Facility, 60 million doses that will be made available from July through October 2021. Also, Gavi has the option to purchase a further 60 million doses in Q4 2021 and 50 million more doses in the first half of 2022, if necessary. This equates to a potential total of 170 million doses of the Sinopharm vaccine that could be made available to self-financing participants of the Facility as well as participants supported by the Gavi COVAX advance market commitment (AMC). READ: COVAX: US welcomes shipment of 2.5mn vaccine doses to Bangladesh   The Sinovac APA also enables Q3 supply, with Gavi committing to purchase, on behalf of the COVAX Facility, 50 million doses to be made available from July through September 2021. Also, Gavi has the option to purchase a further 150 million doses in Q4 2021 and 180 million more doses in the first half of 2022. In total, up to 380 million potential doses of the Sinovac vaccine could be available to both self-financing participants of the Facility and those supported by the Gavi COVAX AMC. The COVAX Facility portfolio, administered by Gavi, currently consists of agreements related to 11 vaccines and vaccine candidates – AstraZeneca/Oxford, Clover, Johnson & Johnson, Moderna, Novavax, Pfizer-BioNTech, Sanofi/GSK, SII-Covishield, SII-Covovax, Sinopharm and Sinovac – providing participants access to a diverse range of vaccines suitable for use in varied contexts and settings and to mitigate against the risk of research and development failures, regulatory delays and supply constraints. READ: COVAX calls for equal recognition of all approved vaccines Gavi has recently published an updated Facility global supply forecast, which shows that thanks to several deals with manufacturers and donations from countries with excess supply, COVAX is on track to deliver more than 2 billion doses by early 2022. Of these, 1.8 billion fully donor-funded doses will be available for the 92 lower-income participants eligible for support by the Gavi COVAX AMC.

The route out of the pandemic now seems far longer and rougher for poorer countries while Americans, Britons and Canadians are rolling up their sleeves to receive Covid-19 shots.

Following reports in Hong Kong that a man had contracted coronavirus for a second time after an interval of more than four months, the UN health agency said the likely possibility of reinfection is slim.

Although politicians and public health leaders have publicly committed to equitably sharing, the top global initiative for coronavirus vaccine that works may allow rich countries to reinforce their own stockpiles while making fewer doses available for the poor ones.

Canada Bangladesh Chamber of Commerce and Industry (CanCham Bangladesh) has said voting for Canada in the Security Council by Bangladesh will accelerate the growing bilateral trade to a new height.

Prime Minister Sheikh Hasina on Thursday said the COVID-19 pandemic showed that infectious diseases know no borders and do not differentiate between the weak and the powerful.

The Global Vaccine Summit will be held in London on Thursday which will look at progress since 2000, and how countries and front-line health workers are successfully addressing the crisis and maintaining essential vaccination services.